Multi-Omics Mendelian Randomization Analysis for IBS Drug Targets

A study by Huiwen Ke integrates GWAS and eQTL data to identify potential drug targets for irritable bowel syndrome. The analysis used summary statistics from a GWAS with 53,400 cases and 433,201 controls, evaluating 5,642 druggable genes. Results were validated with colocalization analysis and a phenome-wide association study.

Use Cases

• Prioritizing candidate drug targets based on causal genetic associations identified through Mendelian randomization.
• Evaluating potential on-target adverse effects using phenome-wide association study (PheWAS) results.
• Predicting therapeutic compounds for candidate targets using molecular docking simulations.
• Repurposing existing drugs like captopril and menadione for IBS treatment based on predicted protein binding.

Strengths

• Integrates large-scale genetic data from a GWAS with 53,400 cases and 433,201 controls.
• Evaluates causal effects for 5,642 potential druggable protein-coding genes.
• Includes validation steps via colocalization analysis and PheWAS to assess adverse effects.
• Provides specific odds ratios for candidate genes EP300 (OR: 1.128) and P2RY14 (OR: 1.118).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (17.0 KB), suggesting it contains summary results rather than raw genetic data.

Provenance

Source

figshare

Collection Method

Systematic druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL summary statistics.

Freshness

Last updated 2026-05-18 22:02:53; freshness should be verified.